Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.69 |
| ▸ | NAAA | Q02083 | 1/20 | 0.65 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.58 |
| ▸ | FAAH | O00519 | 4/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.54 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | POLA1 | P09884 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4093621 | 1.00 | CASP2 (0.69) | CASP2NAAAEPHX1FAAHCA12 | |
| SCHEMBL10728553 | 0.92 | CASP2 (0.57) | CASP2NAAAEPHX1FAAHCA12 | |
| SCHEMBL28279281 | 0.91 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHCA12 | |
| SCHEMBL8576702 | 0.91 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHCA12 | |
| SCHEMBL9118774 | 0.91 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHCA12 | |
| SCHEMBL23052003 | 0.91 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHCA12 | |
| SCHEMBL6584132 | 0.91 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHCA12 | |
| SCHEMBL9118282 | 0.91 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHCA12 | |
| SCHEMBL28569352 | 0.91 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHCA12 | |
| SCHEMBL14073969 | 0.91 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9770442-B2 | Self-assembling amphiphilic polymers as anti-cancer agents | ALLEXCEL INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20100239659-A1 | SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTI-CANCER AGENTS | ALLEXCEL., INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100008938-A1 | SELF ASSEMBLING AMPHIPHILIC POLYMERS AS ANTIVIRAL AGENTS | ALLEXCEL, INC. | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100008938-A1 | SELF ASSEMBLING AMPHIPHILIC POLYMERS AS ANTIVIRAL AGENTS | PICALM, CLTA, HAVCR2 | CASP2 3205/4885NAAA 1019/4885EPHX1 3061/4885 |
| US-20100239659-A1 | SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTI-CANCER AGENTS | CD44, EPCAM, EGFR | CASP2 3257/4885NAAA 1109/4885EPHX1 2622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.